Stay updated with breaking news from Nasdaq Hook. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) had its price target lowered by research analysts at HC Wainwright from $6.50 to $5.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Separately, Royal Bank of Canada restated an “outperform” rating and […]
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) had its target price decreased by investment analysts at HC Wainwright from $6.50 to $5.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Separately, Royal Bank of Canada reaffirmed an “outperform” rating and […]
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority...